Is Zymeworks Inc. (ZYME) a Buy, Sell, or Hold?
Zymeworks Inc.
NASDAQ:ZYME
$24.66 USD
-$0.28 (-1.12%)
- Volume
- 345.95K
- Average Volume
- 673.72K
- Market Capitalization
- $1.81B
- P/E Ratio
- -18.01
- Dividend Yield
- 0.00%
- Price Target
- $41.50
- Year High
- $29.75
- Year Low
- $11.51
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $10.82
NUMBER OF INSIDERS BUYING (LAST 12 MONTHS)
46
NUMBER OF INSIDERS SELLING (LAST 12 MONTHS)
20
AMOUNT OF INSIDER SELLING (LAST 12 MONTHS)
$ 576.43K
ZYME Estimated and Actual Revenue by Quarter
Get MSFT Insider Trade Alerts
ZYME Insider Trading History
| Insider Name | Title | Date | Transaction | Cost | Filing Date |
|---|---|---|---|---|---|
| Hollywood Mark | officer: EVP & Chief Operating Officer | 2026-07-06 | A-Award | 22.22 | 2026-07-06 |
| Schneider Paul R | officer: EVP, General Counsel | 2026-05-13 | A-Award | 24.57 | 2026-05-15 |
| Schneider Paul R | officer: EVP, General Counsel | 2026-05-13 | A-Award | 0 | 2026-05-15 |
| Schneider Paul R | officer: EVP, General Counsel | 2026-05-13 | 0 | 2026-05-15 | |
| Schayowitz Adam | officer: See Remarks | 2026-04-09 | A-Award | 0 | 2026-04-10 |
| Schayowitz Adam | officer: See Remarks | 2026-04-09 | A-Award | 27.35 | 2026-04-10 |
| Schayowitz Adam | officer: See Remarks | 2026-04-09 | A-Award | 0 | 2026-04-10 |
| Platshon Scott | officer: EVP, Chief Business Officer | 2026-04-09 | A-Award | 0 | 2026-04-10 |
| Platshon Scott | officer: EVP, Chief Business Officer | 2026-04-09 | A-Award | 27.35 | 2026-04-10 |
| Platshon Scott | officer: EVP, Chief Business Officer | 2026-04-09 | A-Award | 0 | 2026-04-10 |
| Schayowitz Adam | officer: See Remarks | 2026-04-09 | 0 | 2026-04-10 | |
| Schayowitz Adam | officer: See Remarks | 2026-04-09 | 16.92 | 2026-04-10 | |
| Schayowitz Adam | officer: See Remarks | 2026-04-09 | 0 | 2026-04-10 | |
| Platshon Scott | officer: EVP, Chief Business Officer | 2026-04-09 | 22.99 | 2026-04-10 | |
| Platshon Scott | officer: EVP, Chief Business Officer | 2026-04-09 | 0 | 2026-04-10 | |
| Platshon Scott | officer: EVP, Chief Business Officer | 2026-04-09 | 0 | 2026-04-10 | |
| Stafford Kristin | officer: EVP, Chief Financial Officer | 2026-04-06 | A-Award | 25.84 | 2026-04-07 |
| Stafford Kristin | officer: EVP, Chief Financial Officer | 2026-04-06 | A-Award | 0 | 2026-04-07 |
| Stafford Kristin | officer: EVP, Chief Financial Officer | 2026-04-06 | A-Award | 0 | 2026-04-07 |
| Stafford Kristin | officer: EVP, Chief Financial Officer | 2026-04-01 | 0 | 2026-04-07 | |
| Mekan Sabeen | officer: SVP & Chief Medical Officer | 2026-02-01 | 0 | 2026-02-02 | |
| Mekan Sabeen | officer: SVP & Chief Medical Officer | 2026-02-01 | 11.75 | 2026-02-02 | |
| Mekan Sabeen | officer: SVP & Chief Medical Officer | 2026-02-01 | 23.16 | 2026-02-02 | |
| Mekan Sabeen | officer: SVP & Chief Medical Officer | 2026-02-01 | 0 | 2026-02-02 | |
| Mekan Sabeen | officer: SVP & Chief Medical Officer | 2026-02-01 | 0 | 2026-02-02 | |
| Hollywood Mark | officer: EVP & Chief Operating Officer | 2026-01-12 | M-Exempt | 0 | 2026-01-13 |
| Hollywood Mark | officer: EVP & Chief Operating Officer | 2026-01-12 | S-Sale | 22.6735 | 2026-01-13 |
| Hollywood Mark | officer: EVP & Chief Operating Officer | 2026-01-12 | A-Award | 23.16 | 2026-01-13 |
| Hollywood Mark | officer: EVP & Chief Operating Officer | 2026-01-12 | A-Award | 0 | 2026-01-13 |
| Hollywood Mark | officer: EVP & Chief Operating Officer | 2026-01-12 | A-Award | 0 | 2026-01-13 |
| Hollywood Mark | officer: EVP & Chief Operating Officer | 2026-01-12 | M-Exempt | 0 | 2026-01-13 |
| Hollywood Mark | officer: EVP & Chief Operating Officer | 2026-01-09 | 0 | 2026-01-13 | |
| Hollywood Mark | officer: EVP & Chief Operating Officer | 2026-01-09 | 34.82 | 2026-01-13 | |
| Hollywood Mark | officer: EVP & Chief Operating Officer | 2026-01-09 | 0 | 2026-01-13 | |
| Hollywood Mark | officer: EVP & Chief Operating Officer | 2026-01-09 | 10.56 | 2026-01-13 | |
| Hollywood Mark | officer: EVP & Chief Operating Officer | 2026-01-09 | 8 | 2026-01-13 | |
| Hollywood Mark | officer: EVP & Chief Operating Officer | 2026-01-09 | 7 | 2026-01-13 | |
| Hollywood Mark | officer: EVP & Chief Operating Officer | 2026-01-09 | 15.23 | 2026-01-13 | |
| Hollywood Mark | officer: EVP & Chief Operating Officer | 2026-01-09 | 13.22 | 2026-01-13 | |
| Hollywood Mark | officer: EVP & Chief Operating Officer | 2026-01-09 | 35.2 | 2026-01-13 | |
| Cherry Brian N | director | 2026-01-12 | A-Award | 23.16 | 2026-01-13 |
| Cherry Brian N | director | 2026-01-12 | A-Award | 0 | 2026-01-13 |
| Cherry Brian N | director | 2026-01-12 | 0 | 2026-01-13 | |
| Smith Jeffrey T L | officer: EVP & Chief Medical Officer | 2026-01-12 | M-Exempt | 0 | 2026-01-12 |
| Smith Jeffrey T L | officer: EVP & Chief Medical Officer | 2026-01-12 | M-Exempt | 0 | 2026-01-12 |
| Smith Jeffrey T L | officer: EVP & Chief Medical Officer | 2026-01-12 | S-Sale | 22.6735 | 2026-01-12 |
| Ciongoli Gregory Austin | director | 2026-01-12 | A-Award | 23.16 | 2026-01-12 |
| Ciongoli Gregory Austin | director | 2026-01-12 | A-Award | 0 | 2026-01-12 |
| Neu Kelvin | director | 2026-01-12 | A-Award | 23.16 | 2026-01-12 |
| Neu Kelvin | director | 2026-01-12 | A-Award | 0 | 2026-01-12 |
| Landry Robert E | director | 2026-01-12 | A-Award | 23.16 | 2026-01-12 |
| Landry Robert E | director | 2026-01-12 | A-Award | 0 | 2026-01-12 |
| Cesano Alessandra | director | 2026-01-12 | A-Award | 23.16 | 2026-01-12 |
| Cesano Alessandra | director | 2026-01-12 | A-Award | 0 | 2026-01-12 |
| Campoy Carlos | director | 2026-01-12 | A-Award | 23.16 | 2026-01-12 |
| Campoy Carlos | director | 2026-01-12 | A-Award | 0 | 2026-01-12 |
| Mahony Susan | director | 2026-01-12 | A-Award | 23.16 | 2026-01-12 |
| Mahony Susan | director | 2026-01-12 | A-Award | 0 | 2026-01-12 |
| Moore Paul Andrew | officer: Chief Scientific Officer | 2026-01-12 | A-Award | 23.16 | 2026-01-12 |
| Moore Paul Andrew | officer: Chief Scientific Officer | 2026-01-12 | A-Award | 0 | 2026-01-12 |
| Moore Paul Andrew | officer: Chief Scientific Officer | 2026-01-12 | M-Exempt | 0 | 2026-01-12 |
| Moore Paul Andrew | officer: Chief Scientific Officer | 2026-01-12 | S-Sale | 22.6735 | 2026-01-12 |
| Moore Paul Andrew | officer: Chief Scientific Officer | 2026-01-12 | A-Award | 0 | 2026-01-12 |
| Moore Paul Andrew | officer: Chief Scientific Officer | 2026-01-12 | M-Exempt | 0 | 2026-01-12 |
| Galbraith Kenneth | director, officer: Chair & CEO | 2026-01-12 | M-Exempt | 0 | 2026-01-12 |
| Galbraith Kenneth | director, officer: Chair & CEO | 2026-01-12 | S-Sale | 22.6735 | 2026-01-12 |
| Galbraith Kenneth | director, officer: Chair & CEO | 2026-01-12 | A-Award | 0 | 2026-01-12 |
| Galbraith Kenneth | director, officer: Chair & CEO | 2026-01-12 | A-Award | 23.16 | 2026-01-12 |
| Galbraith Kenneth | director, officer: Chair & CEO | 2026-01-12 | A-Award | 0 | 2026-01-12 |
| Galbraith Kenneth | director, officer: Chair & CEO | 2026-01-12 | M-Exempt | 0 | 2026-01-12 |
| PATTERSON LEONE D | officer: EVP, Chief Bus & Fin Officer | 2026-01-06 | A-Award | 10.55 | 2026-01-07 |
| Smith Jeffrey T L | officer: EVP & Chief Medical Officer | 2026-01-05 | M-Exempt | 0 | 2026-01-05 |
| Smith Jeffrey T L | officer: EVP & Chief Medical Officer | 2026-01-05 | M-Exempt | 0 | 2026-01-05 |
| Smith Jeffrey T L | officer: EVP & Chief Medical Officer | 2026-01-05 | S-Sale | 25.0969 | 2026-01-05 |
| Galbraith Kenneth | director, officer: Chair & CEO | 2026-01-05 | M-Exempt | 0 | 2026-01-05 |
| Galbraith Kenneth | director, officer: Chair & CEO | 2026-01-05 | S-Sale | 25.0969 | 2026-01-05 |
| Galbraith Kenneth | director, officer: Chair & CEO | 2026-01-05 | M-Exempt | 0 | 2026-01-05 |
| Galbraith Kenneth | director, officer: Chair & CEO | 2026-01-05 | S-Sale | 25.0969 | 2026-01-05 |
| Galbraith Kenneth | director, officer: Chair & CEO | 2026-01-05 | M-Exempt | 0 | 2026-01-05 |
| Galbraith Kenneth | director, officer: Chair & CEO | 2026-01-05 | M-Exempt | 0 | 2026-01-05 |
| Moore Paul Andrew | officer: Chief Scientific Officer | 2026-01-05 | M-Exempt | 0 | 2026-01-05 |
| Moore Paul Andrew | officer: Chief Scientific Officer | 2026-01-05 | M-Exempt | 0 | 2026-01-05 |
| Moore Paul Andrew | officer: Chief Scientific Officer | 2026-01-05 | S-Sale | 25.0969 | 2026-01-05 |
| Moore Paul Andrew | officer: Chief Scientific Officer | 2026-01-05 | S-Sale | 25.0969 | 2026-01-05 |
| Moore Paul Andrew | officer: Chief Scientific Officer | 2026-01-05 | M-Exempt | 0 | 2026-01-05 |
| Moore Paul Andrew | officer: Chief Scientific Officer | 2026-01-05 | M-Exempt | 0 | 2026-01-05 |
| Galbraith Kenneth | director, officer: Chair & CEO | 2025-12-22 | M-Exempt | 0 | 2025-12-22 |
| Galbraith Kenneth | director, officer: Chair & CEO | 2025-12-22 | S-Sale | 27.0222 | 2025-12-22 |
| Galbraith Kenneth | director, officer: Chair & CEO | 2025-12-22 | M-Exempt | 0 | 2025-12-22 |
| Ciongoli Gregory Austin | director | 2025-08-12 | A-Award | 12.02 | 2025-08-12 |
| Ciongoli Gregory Austin | director | 2025-08-11 | A-Award | 12.44 | 2025-08-12 |
| Landry Robert E | director | 2025-08-11 | A-Award | 12.44 | 2025-08-12 |
| Landry Robert E | director | 2025-08-10 | 0 | 2025-08-12 | |
| Ciongoli Gregory Austin | director | 2025-08-10 | 0 | 2025-08-12 | |
| Ciongoli Gregory Austin | director | 2025-08-10 | 0 | 2025-08-12 | |
| Ciongoli Gregory Austin | director | 2025-08-10 | 0 | 2025-08-12 | |
| EcoR1 Capital, LLC | director, 10 percent owner: | 2025-06-26 | X-InTheMoney | 0.0001 | 2025-06-27 |
| EcoR1 Capital, LLC | director, 10 percent owner: | 2025-06-26 | F-InKind | 12.71 | 2025-06-27 |
| EcoR1 Capital, LLC | director, 10 percent owner: | 2025-06-26 | X-InTheMoney | 0.0001 | 2025-06-27 |
| EcoR1 Capital, LLC | director, 10 percent owner: | 2025-05-19 | P-Purchase | 11.7821 | 2025-05-19 |